Latest & greatest articles for terazosin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on terazosin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on terazosin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for terazosin

1. Terazosin

Terazosin Top results for terazosin - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for terazosin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

2. WITHDRAWN: Terazosin for benign prostatic hyperplasia. (Abstract)

WITHDRAWN: Terazosin for benign prostatic hyperplasia. Lower urinary tract symptoms associated with benign prostatic obstruction (BPO) occur in up to 70% of men over the age of 60 years. To relieve these bothersome symptoms, treatment options include alpha-antagonists, also know as alpha-blockers.We conducted a systematic review to evaluate the effectiveness and adverse effects of the alpha-blocker, terazosin, for treatment of urinary symptoms associated with BPO.Trials were searched (...) in computerized general and specialized databases (MEDLINE, Cochrane Library), by checking bibliographies, and by contacting manufacturers and researchers.Studies were included if they (1) were randomized trials of at least 1 month duration, and (2) included men with symptomatic BPO and compared terazosin with placebo or active controls.Study, patient characteristics and outcomes data were extracted in duplicate onto standardized forms utilizing a prospectively developed protocol. The main outcome measure

2011 Cochrane

3. Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review

Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

4. Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review. (Full text)

Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review. The effectiveness and safety of tamsulosin and terazosin for patients with benign prostatic hyperplasia (BPH) was evaluated by literature review. PubMed, Embase, the Cochrane Library, Chinese biomedicine literature database (CBM), reference lists of reports, and reviews were searched for randomized controlled trials (RCTs), or quasi-RCTs of tamsulosin versus terazosin in BPH. Twelve studies involving 2,816 men (...) were included. Outcomes included international prostate symptom score (IPSS), quality of life (QOL), maximum urinary flow rate (Q(max)), average urinary flow rate (Q(ave)), residual volume, prostate volume, and adverse effect (dizziness, severe hypotension, dry mouth). Relative risk was calculated for dichotomous data. Sensitivity analyses assessed the influence of baseline symptom severity. We found that tamsulosin is better than terazosin when assessed by IPSS (weighted mean difference (WMD

2009 Systems biology in reproductive medicine PubMed abstract

5. Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects. (Abstract)

Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects. 12356082 2002 10 18 2018 01 06 0022-5347 168 4 Pt 1 2002 Oct The Journal of urology J. Urol. Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects. 1657-8 Kaplan Steven A SA eng Journal Article United States J Urol 0376374 0022-5347 2002 10 3 4 0 2002 10 3 4 1 2002 10 3 4 0 ppublish 12356082 S0022-5347(05)64537-5

2002 The Journal of urology

6. Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects. (Abstract)

Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects. To systematically review and evaluate the effectiveness and adverse effects of the alpha-antagonist, terazosin, for treating urinary symptoms associated with benign prostatic obstruction (BPO).Studies were sought and included in the review if they were randomized trials of at least 1 month duration, involved men with symptomatic BPO and compared terazosin with placebo or active (...) controls. The study, patient characteristics and outcome data were extracted in duplicate onto standardized forms using a prospectively developed protocol.Seventeen studies involving 5151 men met the inclusion criteria, i.e. placebo-controlled (10), alpha-blockers (seven), finasteride alone or combined with terazosin and placebo (one), and microwave therapy (one). The study duration was 4-52 weeks; the mean age of the men was 65 years and 82% were white. Baseline urological symptom scale scores

2002 BJU international

7. Terazosin for benign prostatic hyperplasia. (Abstract)

Terazosin for benign prostatic hyperplasia. Lower urinary tract symptoms associated with benign prostatic obstruction (BPO) occur in up to 70% of men over the age of 60 years. To relieve these bothersome symptoms, treatment options include alpha-antagonists, also know as alpha-blockers.We conducted a systematic review to evaluate the effectiveness and adverse effects of the alpha-blocker, terazosin, for treatment of urinary symptoms associated with BPO.Trials were searched in computerized (...) general and specialized databases (MEDLINE, Cochrane Library), by checking bibliographies, and by contacting manufacturers and researchers.Studies were included if they (1) were randomized trials of at least 1 month duration, and (2) included men with symptomatic BPO and compared terazosin with placebo or active controls.Study, patient characteristics and outcomes data were extracted in duplicate onto standardized forms utilizing a prospectively developed protocol. The main outcome measure

2002 Cochrane database of systematic reviews (Online)

8. Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. (Abstract)

Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. To determine the effectiveness of the long-acting alpha(1)-adrenergic receptor blocking agent terazosin compared with placebo on lower urinary tract symptoms and peak urinary flow rate in men with clinical benign prostatic hyperplasia.A formal meta-analysis of all nine randomized trials of terazosin using both an Empirical Bayes and a fully Bayesian approach was conducted. A pooled analysis (...) was conducted on those studies in which patients had a baseline assessment of prostate volume by transrectal ultrasonography.No evidence of heterogeneity was found in the estimated effects of terazosin on the change in peak flow rates in the studies. Terazosin treatment was associated with an increase in the peak flow rate of 1.4 mL/s (95% confidence interval [1.0, 1.7]) compared with placebo. Terazosin resulted in an average reduction of 2.2 points over placebo (95% confidence interval [1.6, 3.0

2001 Urology

9. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. (Abstract)

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. Men with benign prostatic hyperplasia can be treated with alpha 1-adrenergic-antagonist drugs that relax prostatic smooth muscle or with drugs that inhibit 5 alpha-reductase and therefore reduce tissue androgen concentrations. However, the effects of the two types of drugs have not been compared.We compared the safety and efficacy (...) of placebo, terazosin (10 mg daily), finasteride (5 mg daily), and the combination of both drugs in 1229 men with benign prostatic hyperplasia. American Urological Association symptom scores and peak urinary-flow rates were determined at base line and periodically for one year.The mean changes from base line in the symptom scores in the placebo, finasteride, terazosin, and combination-therapy groups at one year were decreases of 2.6, 3.2, 6.1, and 6.2 points, respectively (P<0.001 for the comparisons

1996 NEJM Controlled trial quality: uncertain

10. The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia

The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia Hillman A L, Schwartz J S, Willian M K, Peskin E, Roehrborn C G, Oesterling J E, Mason M F, Maurath C J, Deverka P A, Padley R J Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Terazosin in the treatment of moderate to severe benign prostatic hyperplasia. Type of intervention Treatment; palliative care. Economic study type Cost-effectiveness analysis. Study population Patients 55

1996 NHS Economic Evaluation Database.

11. Economic modelling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia

Economic modelling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia Economic modelling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia Economic modelling to assess the costs of treatment with finasteride, terazosin, and transurethral (...) ) treatment with finasteride, terazosin, and transurethral resection of the prostate for men (TURP). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Hypothetical population of men aged 55-75 years with at least moderate symptoms of prostatism. Setting The practice setting was hospital. The economic study was carried out in the US. Dates to which data relate Effectiveness data were obtained between 1988-1994. Resource data were obtained between 1994-1995

1995 NHS Economic Evaluation Database.

12. Terazosin: pharmacokinetics and the effect of age and dose on the incidence of adverse events. (Abstract)

Terazosin: pharmacokinetics and the effect of age and dose on the incidence of adverse events. Terazosin is a new, long-acting, selective, postsynaptic alpha 1-adrenergic receptor antagonist with a chemical structure similar to that of prazosin. In this article the pharmacokinetics of terazosin are reviewed, and the incidence of adverse events in a dose-response study and a meta-analysis of 20 placebo-controlled trials involving a total of 1814 patients is presented. Peak plasma concentrations (...) of terazosin are achieved 1 to 2 hours after oral administration. The relatively long half-life of terazosin (12 hours) enables it to be administered in a once-a-day regimen. Dose and plasma levels of terazosin show a linear relationship. Terazosin is rapidly and completely absorbed after oral administration. The pharmacokinetics of terazosin are not significantly affected by food, age, hypertension, or renal impairment. Adverse events after the administration of terazosin are usually minor and not age

1991 American heart journal